What Is Epithalon? Definition and What Research Reports

The plain definition

Epithalon is a laboratory-made peptide built from four amino acids — alanine, glutamic acid, aspartic acid and glycine — joined in that order. Peptides are short chains of amino acids, the same building blocks that make up proteins, and at four residues epithalon is about as short as a peptide gets. It was designed in Russian research programmes as a simplified, chemically defined stand-in for epithalamin, a preparation extracted from the pineal gland of animals. In the published literature it is studied almost entirely as an experimental substance in cell cultures and laboratory animals, and it is not an approved drug in the United States, the European Union or the United Kingdom.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any substance you are considering. Nothing here describes how any compound should be obtained or administered.

Epithalon in biochemical terms

Epithalon's sequence is written Ala-Glu-Asp-Gly, which produces the common abbreviation AEDG using the single-letter amino acid code. A 2025 review in International Journal of Molecular Sciences catalogued the peptide's chemistry and the bioactivities attributed to it across decades of published work, describing it as a short pineal-derived tetrapeptide with a broad reported activity profile (PMID 40141333). Reviews of this kind summarise what has been claimed and measured; they do not establish clinical efficacy in humans.

Mechanistically, the peptide is usually discussed in two frames. The first is telomere biology: telomeres are repetitive DNA caps at chromosome ends that shorten with cell division, and telomerase is the enzyme that can extend them. The second is gene regulation: very short peptides have been proposed to interact with DNA or chromatin and thereby alter transcription. A 2020 paper in Molecules examined AEDG peptide during neurogenesis and reported effects on gene expression and protein synthesis, with the authors framing a possible epigenetic mechanism (PMID 32019204). Both frames remain hypotheses supported mainly by laboratory models rather than settled biology.

Names, spellings and related terms

What the published literature reports

Telomeres and telomerase in cell lines

A 2025 study in Biogerontology tested epitalon in human cell lines and reported increased telomere length, with the researchers attributing the change to telomerase upregulation in some lines and to alternative lengthening of telomeres (ALT) activity in others (PMID 40908429). The study was conducted in cultured cells, so its findings describe cellular behaviour in a dish rather than any outcome in a living person. Telomere length in culture is also not a validated marker of health or lifespan in humans.

Gene expression and neural cell models

The Molecules neurogenesis work reported that AEDG peptide stimulated gene expression and protein synthesis in the model used, and the authors discussed epigenetic regulation as a candidate explanation for how a four-residue peptide could exert transcriptional effects (PMID 32019204). This line of work is frequently cited when epithalon is described as a "gene-regulating" peptide, a description that should be read as a mechanistic hypothesis from cell and tissue models.

Antioxidant and cell-repair models

A 2025 paper in Stem Cell Reviews and Reports described epitalon as an antioxidant tetrapeptide and reported enhanced delayed wound healing in an in vitro model of diabetic retinopathy (PMID 40493162). Separately, a 2022 study in Aging reported that epitalon protected mouse oocytes against post-ovulatory ageing-related damage in vitro (PMID 35413689). Both were laboratory models; neither examined a clinical population.

Animal ageing and tumour models

Some of the most-cited work is older rodent research. A 2002 report in Bulletin of Experimental Biology and Medicine described epithalon as decelerating ageing and suppressing the development of breast adenocarcinomas in transgenic her-2/neu mice (PMID 12459848). A 2003 study in International Journal of Molecular Medicine examined epitalon in rat colon carcinogenesis, assessing proliferative activity and apoptosis in colon tumours and mucosa (PMID 12964022). A 2008 paper reported a geroprotective effect of the Ala-Glu-Asp-Gly peptide in male rats kept under different illumination regimens, a design chosen because light exposure disturbs pineal function (PMID 19110597). Findings in genetically modified or chemically treated rodents do not transfer directly to humans.

Immune and stress signalling

A 2002 paper in Neuro Endocrinology Letters examined epitalon's effect on interleukin-1β signal transduction and on thymocyte blast transformation under stress conditions (PMID 12500162). This is often the source behind statements that the peptide "modulates immunity" — a broad phrase that compresses a narrow experimental result.

How the term is used — and where it is misused

In the research literature, "epithalon" names a specific sequence. Outside that literature the word is stretched in several recognisable ways:

• Treated as an anti-ageing therapy. The published base is dominated by cell cultures and rodents. Descriptions of "deceleration of ageing" come from animal models such as the her-2/neu mouse work (PMID 12459848), not from controlled human trials.
• Confused with epithalamin. Epithalamin is an extract containing many components; epithalon is one defined tetrapeptide. Results reported for one are frequently attributed to the other.
• "Telomerase activator" as a fixed property. The 2025 cell-line study reported telomere lengthening through telomerase upregulation or ALT depending on the line (PMID 40908429), which is a more conditional finding than the shorthand suggests.
• Cancer claims in either direction. Rodent carcinogenesis studies examined tumour incidence and cell turnover endpoints (PMID 12964022); they are not evidence about cancer risk or treatment in people.
• Assumed regulatory approval. Epithalon is not an approved medicine in major Western jurisdictions, and material sold under the name is typically labelled research-use-only.

Safety and adverse events: What Studies Report

Published epithalon research has largely focused on efficacy-style endpoints in cells and rodents rather than on systematic safety assessment in humans. The 2025 overview summarised the peptide's bioactivity profile across the literature but did not substitute for the controlled human safety trials that would define an adverse-event profile (PMID 40141333). The animal studies described above reported outcome measures such as tumour incidence and ageing-related endpoints (PMID 12459848, PMID 19110597) rather than graded human adverse events. In practical terms, the absence of large human safety datasets means the tolerability of epithalon in people is not characterised by the published record — an unknown, not a reassurance.

Regulatory status in brief

Epithalon has no marketing authorisation as a drug from the US Food and Drug Administration, the European Medicines Agency or the UK MHRA. It is not a dietary supplement ingredient with recognised status in the United States, and material bearing the name is generally distributed for laboratory research use only. Regulatory classification is separate from scientific interest: a compound can appear in peer-reviewed journals for decades without ever completing the clinical development required for approval.

Related glossary terms

• Tetrapeptide — a peptide of four amino acid residues.
• Telomere — repetitive DNA at chromosome ends that shortens with cell division.
• Telomerase — the enzyme complex that can extend telomeres.
• ALT (alternative lengthening of telomeres) — a recombination-based, telomerase-independent route to telomere maintenance reported alongside telomerase in the 2025 cell-line study (PMID 40908429).
• Geroprotector — a research term for compounds evaluated against ageing endpoints in model systems.
• Pineal gland — the brain structure, best known for melatonin production, from which epithalamin was originally extracted.

References

• Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties (International Journal of Molecular Sciences, 2025)
• Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (Biogerontology, 2025)
• The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy (Stem Cell Reviews and Reports, 2025)
• Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro (Aging, 2022)
• Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice (Bulletin of Experimental Biology and Medicine, 2002)
• Effect of epitalon on interleukin-1beta signal transduction and the reaction of thymocyte blast transformation under stress (Neuro Endocrinology Letters, 2002)
• AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism (Molecules, 2020)
• Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa (International Journal of Molecular Medicine, 2003)
• Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens (Bulletin of Experimental Biology and Medicine, 2008)